Expertise in
5
conditions

Dr. Todd Cooper

Pediatrics
Seattle Children's Hospital
4800 Sand Point Way NE, 
Seattle, WA 
Clinical Trials:Currently Recruiting for 2 Trials
Offers Telehealth
Expertise in
5
conditions
Seattle Children's Hospital
4800 Sand Point Way NE, 
Seattle, WA 

Overview

Todd Cooper is a Pediatrics provider in Seattle, Washington. Dr. Cooper is highly rated in 5 conditions, according to our data. His top areas of expertise are Childhood Acute Myeloid Leukemia, Leukemia, Juvenile Myelomonocytic Leukemia (JMML), Acute Lymphoblastic Leukemia (ALL), and Bone Marrow Transplant.

His clinical research consists of co-authoring 86 peer reviewed articles and participating in 12 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Pediatrics

Licenses

Pediatric Hematology-Oncology in AL

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Premera
  • EPO
  • PPO
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO

Locations

Seattle Children's Hospital
4800 Sand Point Way NE, Seattle, WA 98105

Additional Areas of Focus

Dr. Cooper has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

Pediatric Acute Leukemia (PedAL) Screening Trial - Developing New Therapies for Relapsed Leukemias
Pediatric Acute Leukemia (PedAL) Screening Trial - Developing New Therapies for Relapsed Leukemias
Enrollment Status: Recruiting
Publish Date: January 15, 2026
Intervention Type: Procedure
Study Phase: Phase 1/Phase 2
Pediatric And Young Adult Leukemia Adoptive Therapy (PLAT)-08: A Phase 1 Study Of SC-DARIC33 In Pediatric And Young Adults With Relapsed Or Refractory CD33+ AML
Pediatric And Young Adult Leukemia Adoptive Therapy (PLAT)-08: A Phase 1 Study Of SC-DARIC33 In Pediatric And Young Adults With Relapsed Or Refractory CD33+ AML
Enrollment Status: Recruiting
Publish Date: December 23, 2025
Intervention Type: Biological
Study Drug: SC-DARIC33
Study Phase: Phase 1
Matched Targeted Therapy (MTT) Recommendation for Patients With Recurrent, Refractory, or High Risk Leukemias and Myelodysplastic Syndrome
Matched Targeted Therapy (MTT) Recommendation for Patients With Recurrent, Refractory, or High Risk Leukemias and Myelodysplastic Syndrome
Enrollment Status: Active_not_recruiting
Publish Date: January 09, 2026
Intervention Type: Genetic
Study Phase: Not Applicable
Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML.
Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML.
Enrollment Status: Active_not_recruiting
Publish Date: December 02, 2025
Intervention Type: Drug
Study Drug: Selinexor
Study Phase: Phase 1
A Pilot Study of Vincristine Sulfate Liposome Injection (Marqibo®) in Combination With UK ALL R3 Induction Chemotherapy for Children, Adolescents, and Young Adults With Relapse of Acute Lymphoblastic Leukemia
A Pilot Study of Vincristine Sulfate Liposome Injection (Marqibo®) in Combination With UK ALL R3 Induction Chemotherapy for Children, Adolescents, and Young Adults With Relapse of Acute Lymphoblastic Leukemia
Enrollment Status: Completed
Publish Date: October 22, 2025
Intervention Type: Drug
Study Drug: Marqibo
Study Phase: Phase 1
Epigenetic Reprogramming in Relapse AML: A Phase 1 Study of Decitabine and Vorinostat Followed by Fludarabine, Cytarabine and G-CSF (FLAG) in Children and Young Adults With Relapsed/Refractory AML
Epigenetic Reprogramming in Relapse AML: A Phase 1 Study of Decitabine and Vorinostat Followed by Fludarabine, Cytarabine and G-CSF (FLAG) in Children and Young Adults With Relapsed/Refractory AML
Enrollment Status: Completed
Publish Date: October 16, 2025
Intervention Type: Drug
Study Drugs: Decitabine, Vorinostat, Filgrastim, Fludarabine, Cytarabine
Study Phase: Phase 1
A Feasibility Trial of Everolimus (RAD001),an mTOR Inhibitor, Given in Combination With Multiagent Re-Induction Chemotherapy in Pediatric Patients With Relapsed Acute Lymphoblastic Leukemia (ALL)
A Feasibility Trial of Everolimus (RAD001),an mTOR Inhibitor, Given in Combination With Multiagent Re-Induction Chemotherapy in Pediatric Patients With Relapsed Acute Lymphoblastic Leukemia (ALL)
Enrollment Status: Completed
Publish Date: July 18, 2024
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1/2 Study of CPX-351 (NSC# 775341) Alone Followed by Fludarabine, Cytarabine, and G-CSF (FLAG) for Children With Relapsed Acute Myeloid Leukemia (AML)
A Phase 1/2 Study of CPX-351 (NSC# 775341) Alone Followed by Fludarabine, Cytarabine, and G-CSF (FLAG) for Children With Relapsed Acute Myeloid Leukemia (AML)
Enrollment Status: Completed
Publish Date: September 08, 2023
Intervention Type: Drug, Other, Biological
Study Drugs: Cytarabine, Filgrastim, Fludarabine, Liposomal Daunorubicin, Liposomal Cytarabine
Study Phase: Phase 1/Phase 2
A Phase I Trial of Temsirolimus (CCI-779, Pfizer, Inc.) in Combination With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma
A Phase I Trial of Temsirolimus (CCI-779, Pfizer, Inc.) in Combination With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma
Enrollment Status: Completed
Publish Date: July 27, 2023
Intervention Type: Drug
Study Phase: Phase 1
A Phase I and Dose Expansion Cohort Study of Panobinostat in Combination With Fludarabine and Cytarabine in Pediatric Patients With Refractory or Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome
A Phase I and Dose Expansion Cohort Study of Panobinostat in Combination With Fludarabine and Cytarabine in Pediatric Patients With Refractory or Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome
Enrollment Status: Terminated
Publish Date: November 14, 2018
Intervention Type: Drug
Study Phase: Phase 1
Dasatinib in Combination With Chemotherapy for Relapsed or Refractory Core Binding Factor Acute Myeloid Leukemia: A Phase I Study (AflacLL1401)
Dasatinib in Combination With Chemotherapy for Relapsed or Refractory Core Binding Factor Acute Myeloid Leukemia: A Phase I Study (AflacLL1401)
Enrollment Status: Withdrawn
Publish Date: April 19, 2018
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1 Study of the VEGF Receptor Tyrosine Kinase Inhibitor Axitinib (INLYTA, IND# TBD) in Children With Recurrent or Refractory Solid Tumors
A Phase 1 Study of the VEGF Receptor Tyrosine Kinase Inhibitor Axitinib (INLYTA, IND# TBD) in Children With Recurrent or Refractory Solid Tumors
Enrollment Status: Completed
Publish Date: January 29, 2018
Intervention Type: Drug
Study Phase: Phase 1
View 10 Less Clinical Trials

86 Total Publications

Post Hematopoietic Cell Transplantation Maintenance Therapy With Low-Dose Azacitidine in a Pediatric Population With High-Risk Myeloid Malignancies.
Post Hematopoietic Cell Transplantation Maintenance Therapy With Low-Dose Azacitidine in a Pediatric Population With High-Risk Myeloid Malignancies.
Journal: Transplantation and cellular therapy
Published: September 22, 2025
Similar Doctors
Expertise in
2
conditions
Dr. Bonnie Ramsey
Pediatrics
Expertise in
2
conditions
Dr. Bonnie Ramsey
Pediatrics

Seattle Children's Hospital

4800 Sand Point Way NE, 
Seattle, WA 
 (2078.1 miles away)
206-987-2024
Languages Spoken:
English

Bonnie Ramsey is a Pediatrics provider in Seattle, Washington. Dr. Ramsey is highly rated in 2 conditions, according to our data. Her top areas of expertise are Cystic Fibrosis and Pseudomonas Stutzeri Infections.

Expertise in
19
conditions
Dr. Ghayda M. Mirzaa
Medical Genetics | Pediatrics
Expertise in
19
conditions
Dr. Ghayda M. Mirzaa
Medical Genetics | Pediatrics
4800 Sand Point Way Ne # Oc.9850, 
Seattle, WA 
 (2078.1 miles away)
206-987-2056
Languages Spoken:
English, Arabic, Filipino, German, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Ghayda Mirzaa is a Medical Genetics specialist and a Pediatrics provider in Seattle, Washington. Dr. Mirzaa is highly rated in 19 conditions, according to our data. Her top areas of expertise are Increased Head Circumference, Cortical Dysplasia, Achalasia Microcephaly Syndrome, and Microcephaly. Dr. Mirzaa is currently accepting new patients.

Expertise in
12
conditions
Dr. Hans Ochs
Pediatrics
Expertise in
12
conditions
Dr. Hans Ochs
Pediatrics

Office

1900 9th Ave, 
Seattle, WA 
 (2079.6 miles away)
206-987-7450
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Hans Ochs is a Pediatrics provider in Seattle, Washington. Dr. Ochs is highly rated in 12 conditions, according to our data. His top areas of expertise are Primary Immunodeficiency (PID), Wiskott-Aldrich Syndrome, X-Linked Agammaglobulinemia, and Immunodeficiency with Hyper IgM Type 1.

Frequently Asked Questions about Dr. Todd Cooper

How do I make an appointment with Dr. Todd Cooper?

You can book an appointment with Dr. Todd Cooper by calling their office at 206-987-2000. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Todd Cooper a top-rated expert for Childhood Acute Myeloid Leukemia?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Todd Cooper is classified as an Elite expert for Childhood Acute Myeloid Leukemia, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Todd Cooper specialize in?

While Dr. Todd Cooper is a Pediatrics, they have specific expertise in Childhood Acute Myeloid Leukemia, Leukemia, and Juvenile Myelomonocytic Leukemia (JMML). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Pediatrics.

Does Dr. Todd Cooper participate in research or clinical trials?

Yes. Dr. Todd Cooper has published 86 articles and abstracts on conditions like Childhood Acute Myeloid Leukemia. You can view a list of Dr. Todd Cooper's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Todd Cooper accept my insurance?

Dr. Todd Cooper accepts most major insurance plans, including Cigna and Humana. We recommend calling the office directly at 206-987-2000 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Cooper's expertise for a condition
ConditionClose
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile